NEW YORK (GenomeWeb News) – Proteomics technologies company LifeSensors has licensed technology from Spain's CICbioGUNE research center for use in purifying ubiquitylated proteins that are unstable and difficult to characterize.
LifeSensors said on Tuesday that it signed a worldwide, exclusive license for the Tandem-repeated Ubiquitin Binding Entities (TUBEs) technology, which was developed at CICbioGUNE's proteomics unit.
These TUBEs proteins may be used to capture ubiquitin pathway proteins, which "play key roles in numerous diseases from neurodegeneration to cancer," the company said. The technology can be used to purify ubiquitylated proteins from cells, tissues, and organs, according to LifeSensors.
"We have successfully used the TUBEs to identify novel proteins modified by ubiquitin and protect ubiquitylated proteins from degradation, all without the need for inhibitors or overexpression techniques," CICbioGUNE's Group Leader of Proteomics Manuel Rodriguez said in a statement.
Financial terms of the agreement were not released.